{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:58:52Z","timestamp":1775649532541,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1038\/ncpuro0784","type":"journal-article","created":{"date-parts":[[2007,5,4]],"date-time":"2007-05-04T13:13:40Z","timestamp":1178284420000},"page":"254-260","source":"Crossref","is-referenced-by-count":60,"title":["The management of superficial bladder cancer"],"prefix":"10.1038","volume":"4","author":[{"given":"Guido","family":"Dalbagni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpuro0784_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A et al (2007) Cancer statistics 2007. CA Cancer J Clin 57: 43\u201366","journal-title":"CA Cancer J Clin"},{"key":"BFncpuro0784_CR2","first-page":"1764","volume-title":"Diagnostic Surgical Pathology","author":"VE Reuter","year":"1994","unstructured":"Reuter VE (1994) The lower urinary tract. In Diagnostic Surgical Pathology, 1764\u20131805 (Ed. Sternberg S) New York: Raven"},{"key":"BFncpuro0784_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1159\/000020170","volume":"37","author":"AR Zlotta","year":"2000","unstructured":"Zlotta AR et al. (2000) What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 37: 470\u2013477","journal-title":"Eur Urol"},{"key":"BFncpuro0784_CR4","first-page":"18","volume":"26","author":"MS Soloway","year":"1985","unstructured":"Soloway MS (1985) Overview of treatment of superficial bladder cancer. Urology 26: 18\u201326","journal-title":"Urology"},{"key":"BFncpuro0784_CR5","first-page":"142","volume":"15","author":"HW Herr","year":"1997","unstructured":"Herr HW (1997) High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumor. Semin Urol Oncol 15: 142\u2013146","journal-title":"Semin Urol Oncol"},{"key":"BFncpuro0784_CR6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1046\/j.1464-410X.1997.00431.x","volume":"80","author":"HW Herr","year":"1997","unstructured":"Herr HW (1997) Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 80: 762\u2013765","journal-title":"Br J Urol"},{"key":"BFncpuro0784_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0022-5347(17)59439-2","volume":"113","author":"JP Richie","year":"1975","unstructured":"Richie JP et al. (1975) Radical cystectomy for carcinoma of the bladder: 16 years of experience. J Urol 113: 186\u2013189","journal-title":"J Urol"},{"key":"BFncpuro0784_CR8","first-page":"205","volume":"11","author":"D Paulson","year":"1993","unstructured":"Paulson D (1993) Critical review of radical cystectomy and indicators of prognosis. Semin Urol 11: 205\u2013213","journal-title":"Semin Urol"},{"key":"BFncpuro0784_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0022-5347(17)34865-6","volume":"151","author":"CL Amling","year":"1994","unstructured":"Amling CL et al. (1994) Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151: 31\u201335","journal-title":"J Urol"},{"key":"BFncpuro0784_CR10","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/1097-0142(19940401)73:7<1926::AID-CNCR2820730725>3.0.CO;2-Q","volume":"73","author":"MS Soloway","year":"1994","unstructured":"Soloway MS et al. (1994) Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 73: 1926\u20131931","journal-title":"Cancer"},{"key":"BFncpuro0784_CR11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/1097-0142(19950901)76:5<833::AID-CNCR2820760518>3.0.CO;2-M","volume":"76","author":"JA Freeman","year":"1995","unstructured":"Freeman JA et al. (1995) Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 76: 833\u2013839","journal-title":"Cancer"},{"key":"BFncpuro0784_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0022-5347(17)37707-8","volume":"146","author":"F Pagano","year":"1991","unstructured":"Pagano F et al. (1991) A low dose bacillus Calmette\u2013Guerin regimen in superficial bladder cancer therapy: is it effective? J Urol 146: 32\u201335","journal-title":"J Urol"},{"key":"BFncpuro0784_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0022-5347(05)65969-1","volume":"166","author":"SC Dutta","year":"2001","unstructured":"Dutta SC et al. (2001) Clinical under-staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166: 490\u2013493","journal-title":"J Urol"},{"key":"BFncpuro0784_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/00005392-199907000-00018","volume":"162","author":"HW Herr","year":"1999","unstructured":"Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162: 74\u201376","journal-title":"J Urol"},{"key":"BFncpuro0784_CR15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S0022-5347(05)66532-9","volume":"165","author":"A Brauers","year":"2001","unstructured":"Brauers A et al. (2001) Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 165: 808\u2013810","journal-title":"J Urol"},{"key":"BFncpuro0784_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/01.ju.0000070437.14275.e0","volume":"170","author":"MO Grimm","year":"2003","unstructured":"Grimm MO et al. (2003) Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 170: 433\u2013447","journal-title":"J Urol"},{"key":"BFncpuro0784_CR17","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1097\/01.ju.0000181799.81119.fc","volume":"174","author":"HW Herr","year":"2005","unstructured":"Herr HW (2005) Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette\u2013Guerin therapy. J Urol 174: 2134\u20132137","journal-title":"J Urol"},{"key":"BFncpuro0784_CR18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0094-0143(21)00424-9","volume":"19","author":"DL Lamm","year":"1992","unstructured":"Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19: 573\u2013580","journal-title":"Urol Clin North Am"},{"key":"BFncpuro0784_CR19","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/S0022-5347(17)42052-0","volume":"140","author":"NM Heney","year":"1988","unstructured":"Heney NM et al. (1988) Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol 140: 1390\u20131393","journal-title":"J Urol"},{"key":"BFncpuro0784_CR20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0094-0143(21)00419-5","volume":"19","author":"JB Thrasher","year":"1992","unstructured":"Thrasher JB and Crawford ED (1992) Complications of intravesical chemotherapy. Urol Clin North Am 19: 529\u2013539","journal-title":"Urol Clin North Am"},{"key":"BFncpuro0784_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/00005392-199707000-00018","volume":"158","author":"B Ali-el-Dein","year":"1997","unstructured":"Ali-el-Dein B et al. (1997) Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol 158: 68\u201373","journal-title":"J Urol"},{"key":"BFncpuro0784_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","volume":"93","author":"JL Au","year":"2001","unstructured":"Au JL et al. (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93: 597\u2013604","journal-title":"J Natl Cancer Inst"},{"key":"BFncpuro0784_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0022-5347(17)36577-1","volume":"148","author":"C Bouffioux","year":"1992","unstructured":"Bouffioux C et al. (1992) Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group. J Urol 148: 297\u2013301","journal-title":"J Urol"},{"issue":"Suppl","key":"BFncpuro0784_CR24","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1007\/BF00686919","volume":"35","author":"H Eto","year":"1994","unstructured":"Eto H et al. (1994) Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group. Cancer Chemother Pharmacol 35 (Suppl): S46\u2013S51","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl","key":"BFncpuro0784_CR25","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1007\/BF00686918","volume":"35","author":"N Shinohara","year":"1994","unstructured":"Shinohara N et al. (1994) Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder Cancer Collaborative Group. Cancer Chemother Pharmacol 35 (Suppl): S41\u2013S45","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFncpuro0784_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s002800050448","volume":"38","author":"JR Masters","year":"1996","unstructured":"Masters JR et al. (1996) ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour. Cancer Chemother Pharmacol 38: 59\u201364","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFncpuro0784_CR27","first-page":"139","volume":"4","author":"X Gao","year":"1998","unstructured":"Gao X et al. (1998) Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res 4: 139\u2013143","journal-title":"Clin Cancer Res"},{"key":"BFncpuro0784_CR28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","volume":"149","author":"W Oosterlinck","year":"1993","unstructured":"Oosterlinck W et al. (1993) A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149: 749\u2013752","journal-title":"J Urol"},{"key":"BFncpuro0784_CR29","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","volume":"155","author":"DA Tolley","year":"1996","unstructured":"Tolley DA et al. (1996) The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155: 1233\u20131238","journal-title":"J Urol"},{"key":"BFncpuro0784_CR30","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S0022-5347(01)61606-9","volume":"161","author":"E Solsona","year":"1999","unstructured":"Solsona E et al. (1999) Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 161: 1120\u20131123","journal-title":"J Urol"},{"key":"BFncpuro0784_CR31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1046\/j.1464-410X.1997.00142.x","volume":"79","author":"B Ali-el-Dein","year":"1997","unstructured":"Ali-el-Dein B et al. (1997) Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 79: 731\u2013735","journal-title":"Br J Urol"},{"key":"BFncpuro0784_CR32","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","volume":"171","author":"RJ Sylvester","year":"2004","unstructured":"Sylvester RJ et al. (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171: 2186\u20132190","journal-title":"J Urol"},{"key":"BFncpuro0784_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","volume":"7","author":"SM Di Stasi","year":"2006","unstructured":"Di Stasi SM et al. (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7: 43\u201351","journal-title":"Lancet Oncol"},{"key":"BFncpuro0784_CR34","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S0022-5347(01)67427-5","volume":"153","author":"DL Lamm","year":"1995","unstructured":"Lamm DL et al. (1995) Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153: 1444\u20131450","journal-title":"J Urol"},{"key":"BFncpuro0784_CR35","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/S0022-5347(01)65396-5","volume":"156","author":"A Pawinski","year":"1996","unstructured":"Pawinski A et al. (1996) A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156: 1934\u20131940","journal-title":"J Urol"},{"key":"BFncpuro0784_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0022-5347(17)46972-2","volume":"134","author":"DL Lamm","year":"1985","unstructured":"Lamm DL (1985) Bacillus Calmette\u2013Guerin immunotherapy for bladder cancer. J Urol 134: 40\u201347","journal-title":"J Urol"},{"key":"BFncpuro0784_CR37","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0022-5347(17)36197-9","volume":"149","author":"MD Melekos","year":"1993","unstructured":"Melekos MD et al. (1993) Intravesical bacillus Calmette\u2013Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J Urol 149: 744\u2013748","journal-title":"J Urol"},{"key":"BFncpuro0784_CR38","first-page":"433","volume":"32","author":"DA Yang","year":"1994","unstructured":"Yang DA et al. (1994) Prophylactic effects of zhuling and BCG on postoperative recurrence of bladder cancer [Chinese]. Zhonghua Wai Ke Za Zhi 32: 433\u2013434","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"BFncpuro0784_CR39","first-page":"304","volume":"33","author":"S Zhang","year":"1995","unstructured":"Zhang S et al. (1995) The preventive recurrent results of postoperative intravesical instillation therapy in bladder cancer [Chinese]. Zhonghua Wai Ke Za Zhi 33: 304\u2013306","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"BFncpuro0784_CR40","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","volume":"156","author":"S Krege","year":"1996","unstructured":"Krege S et al. (1996) A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette\u2013Guerin. Participating Clinics. J Urol 156: 962\u2013966","journal-title":"J Urol"},{"key":"BFncpuro0784_CR41","first-page":"23","volume":"Mar\u2013Apr","author":"VN Tkachuk","year":"1996","unstructured":"Tkachuk VN et al. (1996) The use of BCG vaccine for preventing recurrences of superficial bladder cancer [Russian]. Urol Nefrol (Mosk) Mar\u2013Apr: 23\u201325","journal-title":"Urol Nefrol (Mosk)"},{"issue":"Suppl","key":"BFncpuro0784_CR42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/00005392-199904020-00139","volume":"161","author":"R Iantorno","year":"1999","unstructured":"Iantorno R et al. (1999) Randomized prospective study comparing long-term intravesical instillation of BCG after transurethral resection and transurethral resection alone in patients with superficial bladder cancer. J Urol 161 (Suppl): 284","journal-title":"J Urol"},{"key":"BFncpuro0784_CR43","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/S0022-5347(01)67650-X","volume":"153","author":"MA Hudson","year":"1995","unstructured":"Hudson MA and Herr HW (1995) Carcinoma in situ of the bladder. J Urol 153: 564\u2013572","journal-title":"J Urol"},{"key":"BFncpuro0784_CR44","first-page":"187","volume":"310","author":"G Jakse","year":"1989","unstructured":"Jakse G (1989) Intravesical instillation of BCG in carcinoma in situ of the urinary bladder. EORTC protocol 30861. EORTC-GU Group. Prog Clin Biol Res 310: 187\u2013192","journal-title":"Prog Clin Biol Res"},{"key":"BFncpuro0784_CR45","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S0022-5347(17)37452-9","volume":"147","author":"HW Herr","year":"1992","unstructured":"Herr HW et al. (1992) Bacillus Calmette\u2013Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol 147: 1020\u20131023","journal-title":"J Urol"},{"key":"BFncpuro0784_CR46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0022-5347(17)32741-6","volume":"152","author":"RB Nadler","year":"1994","unstructured":"Nadler RB et al. (1994) Durability of the tumor-free response for intravesical bacillus Calmette\u2013Guerin therapy. J Urol 152: 367\u2013373","journal-title":"J Urol"},{"key":"BFncpuro0784_CR47","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","volume":"325","author":"DL Lamm","year":"1991","unstructured":"Lamm DL et al. (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette\u2013Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205\u20131209","journal-title":"N Engl J Med"},{"key":"BFncpuro0784_CR48","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ et al. (2002) Intravesical bacillus Calmette\u2013Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964\u20131970","journal-title":"J Urol"},{"key":"BFncpuro0784_CR49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0022-5347(17)43125-9","volume":"138","author":"MA Hudson","year":"1987","unstructured":"Hudson MA et al. (1987) Single course versus maintenance bacillus Calmette\u2013Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 138: 295\u2013298","journal-title":"J Urol"},{"key":"BFncpuro0784_CR50","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","volume":"5","author":"RA Badalament","year":"1987","unstructured":"Badalament RA et al. (1987) A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette\u2013Guerin therapy of superficial bladder cancer. J Clin Oncol 5: 441\u2013449","journal-title":"J Clin Oncol"},{"key":"BFncpuro0784_CR51","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL et al. (2000) Maintenance bacillus Calmette\u2013Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124\u20131129","journal-title":"J Urol"},{"key":"BFncpuro0784_CR52","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","volume":"163","author":"G Steinberg","year":"2000","unstructured":"Steinberg G et al. (2000) Efficacy and safety of valrubicin for the treatment of Bacillus Calmette\u2013Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163: 761\u2013767","journal-title":"J Urol"},{"key":"BFncpuro0784_CR53","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","volume":"20","author":"G Dalbagni","year":"2002","unstructured":"Dalbagni G et al. (2002) Phase I trial of intravesical gemcitabine in bacillus Calmette\u2013Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20: 3193\u20133198","journal-title":"J Clin Oncol"},{"key":"BFncpuro0784_CR54","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","volume":"24","author":"G Dalbagni","year":"2006","unstructured":"Dalbagni G et al. (2006) Phase II trial of intravesical gemcitabine in bacille Calmette\u2013Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24: 2729\u20132734","journal-title":"J Clin Oncol"},{"key":"BFncpuro0784_CR55","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","volume":"172","author":"MA O'Donnell","year":"2004","unstructured":"O'Donnell MA et al. (2004) Interim results from a national multicenter phase II trial of combination bacillus Calmette\u2013Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172: 888\u2013893","journal-title":"J Urol"},{"key":"BFncpuro0784_CR56","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0022-5347(05)65555-3","volume":"166","author":"BH Bochner","year":"2001","unstructured":"Bochner BH et al. (2001) Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 166: 2295\u20132296","journal-title":"J Urol"},{"key":"BFncpuro0784_CR57","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000472824","volume":"13","author":"M Stockle","year":"1987","unstructured":"Stockle M et al. (1987) Radical cystectomy\u2014often too late? Eur Urol 13: 361\u2013367","journal-title":"Eur Urol"},{"key":"BFncpuro0784_CR58","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S1078-1439(03)00144-3","volume":"22","author":"FJ Bianco Jr","year":"2004","unstructured":"Bianco FJ Jr et al. (2004) Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 22: 290\u2013294","journal-title":"Urol Oncol"},{"key":"BFncpuro0784_CR59","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0022-5347(05)66518-4","volume":"165","author":"JC Kim","year":"2001","unstructured":"Kim JC and Steinberg GD (2001) The limits of bacillus Calmette\u2013Guerin for carcinoma in situ of the bladder. J Urol 165: 745\u2013756","journal-title":"J Urol"},{"key":"BFncpuro0784_CR60","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0090-4295(99)00619-6","volume":"55","author":"DJ Parekh","year":"2000","unstructured":"Parekh DJ et al. (2000) Continent urinary reconstruction versus ileal conduit: a contemporary single-institution comparison of perioperative morbidity and mortality. Urology 55: 852\u2013855","journal-title":"Urology"},{"key":"BFncpuro0784_CR61","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/S0022-5347(05)64166-3","volume":"168","author":"DJ Parekh","year":"2002","unstructured":"Parekh DJ et al. (2002) Orthotopic neobladder following radical cystectomy in patients with high perioperative risk and co-morbid medical conditions. J Urol 168: 2454\u20132456","journal-title":"J Urol"},{"key":"BFncpuro0784_CR62","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0022-5347(01)63173-2","volume":"159","author":"RE Hautmann","year":"1998","unstructured":"Hautmann RE and Paiss T (1998) Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy? J Urol 159: 1845\u20131850","journal-title":"J Urol"}],"container-title":["Nature Clinical Practice Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpuro0784","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpuro0784.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpuro0784.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:15:17Z","timestamp":1684440917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpuro0784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["BFncpuro0784"],"URL":"https:\/\/doi.org\/10.1038\/ncpuro0784","relation":{},"ISSN":["1743-4270","1743-4289"],"issn-type":[{"value":"1743-4270","type":"print"},{"value":"1743-4289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}